X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare PLETHICO PHARMA with Aventis Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PLETHICO PHARMA vs SANOFI INDIA - Comparison Results

SANOFI INDIA 
   Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PLETHICO PHARMA SANOFI INDIA PLETHICO PHARMA/
SANOFI INDIA
 
P/E (TTM) x -1.1 33.6 - View Chart
P/BV x 0.0 6.4 0.3% View Chart
Dividend Yield % 0.0 1.4 -  

Financials

 PLETHICO PHARMA   SANOFI INDIA
EQUITY SHARE DATA
    PLETHICO PHARMA
Mar-14
SANOFI INDIA
Dec-16
PLETHICO PHARMA/
SANOFI INDIA
5-Yr Chart
Click to enlarge
High Rs3954,560 8.7%   
Low Rs314,400 0.7%   
Sales per share (Unadj.) Rs604.41,028.5 58.8%  
Earnings per share (Unadj.) Rs32.5129.0 25.2%  
Cash flow per share (Unadj.) Rs51.3186.0 27.6%  
Dividends per share (Unadj.) Rs068.00 0.0%  
Dividend yield (eoy) %01.5 0.0%  
Book value per share (Unadj.) Rs473.6753.6 62.8%  
Shares outstanding (eoy) m34.0823.03 148.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.44.4 8.1%   
Avg P/E ratio x6.634.7 18.9%  
P/CF ratio (eoy) x4.224.1 17.2%  
Price / Book Value ratio x0.55.9 7.6%  
Dividend payout %052.7 0.0%   
Avg Mkt Cap Rs m7,262103,174 7.0%   
No. of employees `000NA3.6 0.0%   
Total wages/salary Rs m1,5963,592 44.4%   
Avg. sales/employee Rs ThNM6,537.7-  
Avg. wages/employee Rs ThNM991.4-  
Avg. net profit/employee Rs ThNM819.8-  
INCOME DATA
Net Sales Rs m20,59823,686 87.0%  
Other income Rs m386708 54.6%   
Total revenues Rs m20,98424,394 86.0%   
Gross profit Rs m2,8185,281 53.4%  
Depreciation Rs m6421,313 48.9%   
Interest Rs m1,59315 10,621.3%   
Profit before tax Rs m9694,661 20.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-1381,691 -8.2%   
Profit after tax Rs m1,1072,970 37.3%  
Gross profit margin %13.722.3 61.4%  
Effective tax rate %-14.336.3 -39.4%   
Net profit margin %5.412.5 42.9%  
BALANCE SHEET DATA
Current assets Rs m18,87715,673 120.4%   
Current liabilities Rs m11,8966,678 178.1%   
Net working cap to sales %33.938.0 89.2%  
Current ratio x1.62.3 67.6%  
Inventory Days Days3676 47.3%  
Debtors Days Days19822 886.6%  
Net fixed assets Rs m9,8618,098 121.8%   
Share capital Rs m341230 147.9%   
"Free" reserves Rs m12,33117,088 72.2%   
Net worth Rs m16,13917,356 93.0%   
Long term debt Rs m4,7060-   
Total assets Rs m33,14625,400 130.5%  
Interest coverage x1.6311.7 0.5%   
Debt to equity ratio x0.30-  
Sales to assets ratio x0.60.9 66.6%   
Return on assets %8.111.8 69.3%  
Return on equity %6.917.1 40.1%  
Return on capital %12.326.9 45.6%  
Exports to sales %21.424.5 87.3%   
Imports to sales %15.228.0 54.4%   
Exports (fob) Rs m4,4025,801 75.9%   
Imports (cif) Rs m3,1366,627 47.3%   
Fx inflow Rs m4,4027,145 61.6%   
Fx outflow Rs m3,1846,846 46.5%   
Net fx Rs m1,219299 407.5%   
CASH FLOW
From Operations Rs m2,4373,226 75.6%  
From Investments Rs m-6,265-1,555 402.9%  
From Financial Activity Rs m2,490-1,818 -137.0%  
Net Cashflow Rs m-1,337-147 909.6%  

Share Holding

Indian Promoters % 82.7 0.0 -  
Foreign collaborators % 0.0 60.4 -  
Indian inst/Mut Fund % 4.3 14.4 29.9%  
FIIs % 5.5 14.6 37.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 7.5 10.5 71.4%  
Shareholders   10,665 15,184 70.2%  
Pledged promoter(s) holding % 85.7 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PLETHICO PHARMA With:   ELDER PHARMA  FDC LTD.  SUN PHARMA  STRIDES SHASUN LTD  TTK HEALTHCARE  

Compare PLETHICO PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Firm US Markets; Sun Pharma, Software Stocks & Other Top Cues to Sway the Markets Today(Pre-Open)

Indian share markets finished the previous trading session on a strong note amid firm Asian markets after comments from a Federal Reserve official eased worries about faster rate hikes in US.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

A New Quest for the Stock Market's MOST Profitable Ideas...(Smart Contrarian)

Feb 23, 2018

If you want to receive the best ideas in the Indian stick markets...you need to heed this important announcement.

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PLETHICO PHARMA SHARE PRICE


Jun 13, 2016 (Close)

TRACK PLETHICO PHARMA

  • Track your investment in PLETHICO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PLETHICO PHARMA

PLETHICO PHARMA 5-YR ANALYSIS

COMPARE PLETHICO PHARMA WITH

MARKET STATS